What is the 13F Pro Quality Score for LGVN?

13F Pro ranks Longeveron Inc. (LGVN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View LGVN's current score at https://13fpro.ai/research/LGVN (free sign-up required for the full ranking).

Which hedge funds own the most LGVN stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of LGVN include VANGUARD CAPITAL MANAGEMENT, MILLENNIUM MANAGEMENT, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/LGVN as soon as new 13F filings post.

Where does 13F Pro source LGVN data?

All Longeveron Inc. fundamentals and ownership data come directly from SEC EDGAR. Longeveron Inc. files with the SEC under CIK 1721484. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is LGVN in?

Longeveron Inc. (LGVN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is LGVN research updated on 13F Pro?

LGVN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Longeveron Inc.(LGVN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1721484 LGVN stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $5.6M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

LGVN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Longeveron Inc. (LGVN), a Healthcare sector company. LGVN is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $5.6m in revenue. Based on the latest XBRL financial filings (Q1 2026), Longeveron Inc. reports quarterly revenue of $398.0K, net income of $-4.7M, free cash flow of $-4.4M. Top institutional holders of LGVN by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, MILLENNIUM MANAGEMENT, BlackRock,, based on the most recent SEC filings. LGVN trades on the Nasdaq exchange and files with the SEC under CIK 1721484. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LGVN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Longeveron Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$398.0K

Net Income

Q1 2026

$-4.7M

Free Cash Flow

Q1 2026

$-4.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-49.9% YoY

$1.2MFY 2025

FY22 $1.2MFY23 $709.0KFY24 $2.4MFY25 $1.2M

Net Income

-42.1% YoY

$-22.7MFY 2025

FY22 $-18.8MFY23 $-21.4MFY24 $-16.0MFY25 $-22.7M

Operating Income

-40.9% YoY

$-23.3MFY 2025

FY22 $-18.0MFY23 $-21.0MFY24 $-16.5MFY25 $-23.3M

EPS (Diluted)

+50.8% YoY

$-1.29FY 2025

FY22 $-0.90FY23 $-10.22FY24 $-2.62FY25 $-1.29

Total Assets

-59.9% YoY

$10.3MFY 2025

FY22 $27.4MFY23 $12.1MFY24 $25.6MFY25 $10.3M

Total Debt

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Op. Cash Flow

-34.4% YoY

$-18.6MFY 2025

FY22 $-14.0MFY23 $-19.0MFY24 $-13.9MFY25 $-18.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$1.2M -49.9%	$2.4M +237.4%	$709.0K -42.0%	$1.2M -6.4%	$1.3M -76.8%	$5.6M
Net Income	$-22.7M -42.1%	$-16.0M +25.4%	$-21.4M -13.7%	$-18.8M -10.5%	$-17.0M -358.1%	$-3.7M
Operating Income	$-23.3M -40.9%	$-16.5M +21.4%	$-21.0M -16.5%	$-18.0M -3.4%	$-17.5M -362.0%	$-3.8M
EPS (Diluted)	$-1.29 +50.8%	$-2.62 +74.4%	$-10.22 -1035.6%	$-0.90 +0.0%	$-0.90	—
Total Assets	$10.3M -59.9%	$25.6M +111.6%	$12.1M -55.9%	$27.4M -35.9%	$42.8M +362.8%	$9.2M
Total Debt	—	—	—	—	—	$450.0K
Operating Cash Flow	$-18.6M -34.4%	$-13.9M +27.0%	$-19.0M -36.0%	$-14.0M -45.0%	$-9.6M -307.6%	$-2.4M

AI Insight: LGVN Financial Trends

Longeveron remains pre-revenue with persistent operating losses and equity erosion, though Q1 2026 shows modest cash-burn improvement.

• Revenue has remained at or near $0M across all eight quarters; company has not achieved meaningful commercial traction.

• Operating cash burn averaged $4.4M per quarter through Q4 2025, moderately improved to $4M in Q1 2026.

• Equity contracted from $26M (Q3 2024) to $6M (Q4 2025), a 77% decline, before recovering to $16M in Q1 2026.

⚠ Net loss widened to $7M in Q3 2025 (highest in dataset); no clear path to profitability evident.

⚠ Equity surge from $6M to $16M in Q1 2026 suggests capital raise or accounting adjustment; sustainability unclear.

AI Insight: LGVN Ratio Trends

Longeveron remains deeply unprofitable with ROE deteriorating to -118.2% in Q1 2026, showing no path to profitability.

• ROE worsened from -91.6% in Q2 2024 to -118.2% in Q1 2026, indicating accelerating shareholder value destruction.

• ROA declined from -59.1% in Q3 2024 to -89.3% in Q1 2026, signaling deteriorating asset efficiency.

⚠ Q1 2026 ROE of -118.2% represents a meaningful decline from -116.8% in Q1 2025, suggesting operational momentum is worsening.

⚠ No profitability metrics available for Q3–Q4 2025; data gaps may mask critical quarterly swings.

Get alerted when LGVN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Longeveron Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of LGVN

VANGUARD CAPITAL MANAGEMENT LLC
$563.7K542,032 sh
MILLENNIUM MANAGEMENT LLC
$464.6K446,725 sh
BlackRock, Inc.
$233.2K224,198 sh
GEODE CAPITAL MANAGEMENT, LLC
$211.8K203,618 sh
ADAR1 Capital Management, LLC
$208.0K200,000 sh
JANE STREET GROUP, LLC
$193.1K185,656 sh
Beacon Pointe Advisors, LLC
$104.0K100,000 sh
STATE STREET CORP
$47.2K45,380 sh
VANGUARD FIDUCIARY TRUST CO
$40.3K38,715 sh
Capital Investment Advisory Services, LLC
$27.6K26,525 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$563.7K	542,032
MILLENNIUM MANAGEMENT LLC	$464.6K	446,725
BlackRock, Inc.	$233.2K	224,198
GEODE CAPITAL MANAGEMENT, LLC	$211.8K	203,618
ADAR1 Capital Management, LLC	$208.0K	200,000
JANE STREET GROUP, LLC	$193.1K	185,656
Beacon Pointe Advisors, LLC	$104.0K	100,000
STATE STREET CORP	$47.2K	45,380
VANGUARD FIDUCIARY TRUST CO	$40.3K	38,715
Capital Investment Advisory Services, LLC	$27.6K	26,525

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put LGVN on your watchlist

Track score changes the day Longeveron Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is LGVN a good stock to buy?

13F Pro's AI-powered analysis of Longeveron Inc. (LGVN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LGVN are available on the LGVN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own LGVN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LGVN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Longeveron Inc.'s investment landscape.